IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11382907 B1

PDFFull Text
Date of Patent:
Jul. 12, 2022

Filed:

Apr. 04, 2018

Methods and compositions for treating aging-associated impairments using ccr3-inhibitors

Applicant:

Alkahest, Inc., San Carlos, CA (US);

Inventors:

Steven P. Braithwaite, Redwood City, CA (US);

S. Sakura Minami, San Francisco, CA (US);

Karoly Nikolich, Emerald Hills, CA (US);

Assignee:

Alkahest, Inc., San Carlos, CA (US);

Attorneys:

Mandar A. Joshi

Bret E. Field

Bozicevic, Field & Francis LLP

Primary Examiner:

Shobha Kantamneni

Int. Cl.
CPC ...
A61K 31/4545 (2006.01); A61P 25/00 (2006.01); A61P 25/16 (2006.01); A61K 9/20 (2006.01); A61K 47/02 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 47/26 (2006.01); A61K 47/18 (2017.01); A61K 9/16 (2006.01); A61K 47/40 (2006.01); A61K 9/28 (2006.01); A61K 9/48 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4545 (2013.01); A61K 9/00 (2013.01); A61K 9/0004 (2013.01); A61K 9/008 (2013.01); A61K 9/0075 (2013.01); A61K 9/08 (2013.01); A61K 9/1617 (2013.01); A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/2027 (2013.01); A61K 9/2031 (2013.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01); A61K 9/2077 (2013.01); A61K 9/2095 (2013.01); A61K 9/2813 (2013.01); A61K 9/2866 (2013.01); A61K 9/4858 (2013.01); A61K 47/02 (2013.01); A61K 47/183 (2013.01); A61K 47/26 (2013.01); A61K 47/40 (2013.01); A61P 25/00 (2018.01); A61P 25/16 (2018.01);
Abstract

Methods of improving neurodegenerative disease with CCR3 modulating agents are provided. The methods include administering a therapeutically effective amount of the CCR3 modulating agent to the subject, with a concomitant improvement in cognition, motor, or other neurodegenerative-affected function. Cognitive and motor diseases upon which the methods of the invention can improve cognition include Alzheimer's disease, Parkinson's disease, frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, glaucoma, myotonic dystrophy, vascular dementia, progressive supranuclear palsy.

Find Patent Forward Citations

Loading…